There is little evidence for modification of dosage and administration schedule for sunitinib- and regorafenib-resistant patients, combination of TKIs and local therapy, and treatment of GIST caused by abnormalities other than c-kit or PDGFRA genes. This evidence concerns the gene KIT and gastrointestinal stromal tumor.